Ad Mci

3

Review clinical trials related to Ad Mci. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Temporal Interference Stimulation Treatment in Patients With Cognitive Impairment

This study aims to evaluate the efficacy and safety of temporal interference stimulation (TIS), a non-invasive neuromodulation technique, in improving cognitive function in patients with cognitive impairment. TIS uses two high-frequency currents applied transcranially, which intersect within the brain to generate a low-frequency modulation field. This technique selectively modulates deep brain regions while minimizing the stimulation of superficial cortical layers. Participants will undergo individualized MRI-based modeling to determine the optimal electrode placement and stimulation parameters. The intervention consists of 10 stimulation sessions over a period of 14 days, using either active TIS or sham stimulation. Cognitive assessments, EEG recordings, and functional MRI scans will be conducted at baseline; 5 days after intervention initiation; at the end of the 10-day intervention; and during follow-up assessments at 4 weeks, 8 weeks, and 12 weeks post-intervention to evaluate both immediate and long-term effects on cognitive performance and neural activity. The study aims to determine whether TIS can serve as a feasible and effective neuromodulation strategy for individuals with cognitive impairment.

Participants needed: 60
Trial details
Age: 45-85Biological sex: AllType: InterventionalSponsor: Tianjin Huanhu HospitalUpdated: Jun 11, 2026Locations: 1
Eligibility criteria

meets the criteria for probable AD and MCI due to AD as defined by the 2024 Nati... [+13]

Diagnosis of other types of dementia or major neurological disorders (e.g., stro... [+10]

Status: Recruiting

Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.

The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.

Participants needed: 10
Trial details
Phase: Phase 2Age: 55-90Biological sex: AllType: InterventionalSponsor: Bernard (Barry) BaumelUpdated: May 28, 2026Locations: 1
Eligibility criteria

Adults 55-90 years at the time of signing consent [+4]

Dementia other than AD [+10]

Status: Not yet recruiting

Clinical Multicenter Randomized Controlled Study of Non-invasive Brain Oscillation Modulation in the Treatment of AD-MCI Patients

A multicenter randomized controlled clinical study was conducted in the Xuanwu hospital of Capital Medical University to preliminarily explore the efficacy and safety of transcranial electrical stimulation in the treatment of AD-MCI patients, to clarify the effective mechanism and form an effective clinical treatment plan.

Participants needed: 124
Trial details
Age: 50-85Biological sex: AllType: InterventionalSponsor: Xuanwu Hospital, BeijingUpdated: Jun 24, 2024Locations: 1
Eligibility criteria

Not listed